Part D - Randomised, placebo-controlled, expansion cohort in participants with axSpA clinical trials

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)

This study is testing a new oral medicine called GRWD0715 for axial spondyloarthritis (AxSpA). It aims to stop the immune system from attacking the body's joints, which causes inflammation. We hope to find out if it's safe and effective for people with AxSpA.